Source: Annual Congress 2006 - Prognostic factors in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
H. H. Popper, I. Halbwedl, P. Morbini, P. T. Cagle, B. Murer, C. E. Comin, F. Galateau-Salle, H. Zeren, R. Attanoos, A. Gibbs (Graz, Austria; Pavia, Mestre-Venezia, Florence, Italy; Houston, USA; Caen, France; Adana, Turkey; Cardiff, United Kingdom). Different growth regulation in malignant mesotheliomas in long and short time survivors. Eur Respir J 2006; 28: Suppl. 50, 952

Member's Comments

No comment yet.

Related content which might interest you: Time trends in long term survival of patients operated for primary NSCLC Source: Eur Respir J 2004; 24: Suppl. 48, 41s Year: 2004 Exposure characteristics of patients with different pathological types of malignant mesothelioma Source: Annual Congress 2012 - Abestosis, silicosis and hypersensitivity pneumonitis Year: 2012 Long term survival after resection for non small cell lung cancer significance of hormonal receptors Source: Eur Respir J 2002; 20: Suppl. 38, 185s Year: 2002 Survival time in patients with malignant pleural mesothelioma Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 Characteristics of common and uncommon epidermal growth factor receptros gene mutations in patients with non small cell lung cancer Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 The long non-coding MALAT-1 RNA indicates a poor prognosis in NSCLC and induces migration and tumor growth Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Tracheobronchopulmonary carcinoid tumors surgical management and long term outcome Source: Annual Congress 2008 - Actual challenges in thoracic surgery Year: 2008 Malignant pleural mesothelioma: clinicopathologic and survival characteristic in a consecutive series of 40 patients Source: Annual Congress 2009 - Preoperative functional assessment and surgery for malignant diseases Year: 2009 Neuroendocrine and biologic features of primary tumors and tissue in pulmonary large cell carcinomas Source: Eur Respir J 2004; 24: Suppl. 48, 557s Year: 2004 Short and long term effects of PR. Can patients benefit of a short maintenance program? Source: Annual Congress 2008 - Impact of rehabilitation programmes in COPD and non-COPD patients Year: 2008 (Array)CGH analysis of chromosomal gains and losses in human malignant pleural mesothelioma cell lines: Involved loci and genes Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach Year: 2010 Does long treatment delay affect survival in metastatic non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 BAP1 expression and treatment outcomes in malignant mesothelioma. Source: International Congress 2017 – Pleural disease and mesothelioma: from the bench to the bedside Year: 2017 Is there any advantage of chemotherapy on survival of patients with diffuse malignant pleural mesothelioma? Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003 Potential role of short hairpin RNA targeting epidermal growth factor receptor in growth and sensitivity to drugs of human lung adenocarcinoma cells Source: Eur Respir J 2006; 28: Suppl. 50, 325s Year: 2006 Is gender a prognostic factor in long term survival non-small cell lung cancer? Source: Eur Respir J 2002; 20: Suppl. 38, 185s Year: 2002 Predicting survival in malignant mesothelioma Source: Eur Respir J 2011; 38: 1420-1424 Year: 2011 Survival of patients with extended small cell lung cancer depending on metastases location Source: Annual Congress 2009 - Clinical aspects and epidemiology in lung cancer Year: 2009 Predicting survival in malignant mesothelioma}, Source: Eur Respir J 2012; 40: 799 Year: 2012 Delays in the diagnosis and treatment of primary lung cancer: are longer delays associated with advanced pathological stage? Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology Year: 2008